IBI 302

Drug Profile

IBI 302

Alternative Names: IBI-302

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AP Biosciences
  • Developer Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Complement system protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Solid tumours

Most Recent Events

  • 10 Jul 2018 Discontinued for Solid tumours in China (unspecified route)
  • 10 Jul 2018 Phase-I clinical trials in Age-related macular degeneration (Parenteral) (Innovent Biologics website, July 2018)
  • 04 Aug 2017 Early research in Eye disorders in China (unspecified route) (Innovent website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top